RE:AGM PerspectivesAbout the 8 billions Pierre (and the slides) is talking about, it is not the future value of plasminogene division, it is the value of the annual market. As Pierre said, it will take some years in order to get the BLA for each Pg indications (each application, DFU, Tympanic repair, major burns, lung, mound healing in general) will need an IND followed by a direct phase 2/3 in order to manage perfectly the protocol and dosage. However, these application will be fast track once we get the BLA for Pg CD.
And of course, there will be also the time to penetrate the market, but I believe that from the moment Pg hit the market, with all the off label use possible and the fact that Prometic is the only game in town for a while (the competition would have the same timeline devellopement and approval time), Prometic should be able to grab the whole 8 billions annual market within 5 years.
If you consider a 75% margin, at a conservative P/E of 15, it means 6 billions X 15 / 750 millions shares (approx in 2022) then Pg value would be 120$ a share!
OK this is a very good case scenario. But if you think about PgCD only with a market of 250 millions, it would by itself represent about 5,35$ per share at a P/E of 15 for PgCD only within 2 years from now.
IMHO